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ABSTRACT 
 
  
This project examines transgenic animals in society today.  The project details the 
methods of creating transgenic animals, explores the purpose and reasons they are created, and 
investigates the legal and ethical dilemmas that stem from this controversial practice.  The 
particular use of each transgenic animal in science served as a prelude to a discussion of ethics.  
Views on the ethics of each type of transgenic animal were investigated, as well as the legal 
debates being waged regarding transgenic regulations.  It is clear that the creation and use of 
transgenic animals, and the accompanying moral and legal debates, show the effect of 
technology on society.  While it may continue to be a hotly contested, controversial practice, the 
benefits of transgenic animals are enormous and should continue long into the future.  We 
believe that although animals are jeopardized for human benefit, these benefits are just to great to 
be ignored and transgenic technology should be allowed to continue. 
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PROJECT OBJECTIVE 
 
The objective of this IQP project is to inform the layreader about the topic of transgenic 
animals to allow a discussion of the controversial laws and ethics surrounding the topic.  The 
report details what transgenic animals are, how they are created, and the uses of the various 
transgenic animals that have been created to date.  Once this base of knowledge is established, 
the project goes on to discuss the ethics involved in animal experimentation and the laws that 
oversee their use.  With all the complex aspects that transgenic technology encompasses, this has 
led to a plethora of misinformed opinions on the topic creating more controversy.  This project 
attempts to inform the reader with information on how transgenic animals are made, used, and 
handled so that they are able to form their own opinion on the topic of transgenic technology. 
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CHAPTER 1:  TRANSGENIC ANIMAL DESCRIPTION AND CONSTRUCTION 
 
 A transgenic animal is an animal that carries foreign DNA along with its original DNA. 
The foreign gene is inserted into the animal’s genome by methods of recombinant DNA 
techniques. This allows the animals to have an altered DNA that will produce chemicals that it 
otherwise would not produce through natural means.  This process can yield many benefits such 
as creating disease models for mimicking human disorders, to providing organ donors for 
transplantations, to serving as food, to enhancing animal milk that produces life saving 
pharmaceuticals in it.  This chapter will discuss the methods for creating transgenic animals, and 
the assays used for their screening.  
 
DNA 
 
 DNA, or deoxyribonucleic acid, is one of the two types of molecules that encode genetic 
information (RNA being the other).  DNA is the material that stores and transfers genetic 
characteristics in all life forms, and is the primary component of chromosomes. DNA is a long 
double-stranded polymer that is held together by hydrogen bonds between base pairs of 
nucleotides (Figure-1). DNA is polymerized from monomer units called nucleotides, denoted as 
rungs in the ladder in the figure. These nucleotides are found in four different structures: adenine 
and guanine are purin bases; thymine and cytosine are pyrimidine bases. The adenine always 
pairs with thymine, and guanine always pairs with cytosine. The nucleotides form a paired 
structure which creates a double helix. The DNA is compacted with proteins, including histones, 
to make chromosomes (DNA, 2005). 
  
 
 
 
 
 
 
 
 
 Genes are the basic hereditary factor in DNA.  It is a segment of DNA that contributes to 
the organism’s phenotype or function.  Genes have distinct sequences of
the DNA segment to produce its necessary proteins. The region of the gene that codes for the 
production of a protein are called exons. These exons contain codes that are used in specific 
portions for the completion of the protein. Introns are the parts of a gene 
transcribed into the primary RNA transcript along with the exons, but are subsequently removed 
to make the mature protein are called introns. The introns are removed when the exons are 
spliced together. 
 
RECOMBINANT DNA TECHNOLOGY
 
 Recombinant DNA technology was first developed in the early 1970's by Paul Berg, 
Herbert Boyer, and Stanley Cohen, when they were investigating ways to recombine the DNAs 
of microorganisms.  In order to produce a transgenic animal, its DNA must be manipulated 
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that are initially 
 
Figure-1: Diagram of DNA Double 
Helix Structure.  This structure is formed 
by paired nucleotides, denoted by the 
rungs in the ladder.  The nucleotides are 
represented by: Thymine –red, Adenine-
green, Guanine-purple, and Cytosine-light 
green.  
(http://www.biologycorner.com/resources/
DNA-colored.gif) 
along 
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with foreign DNA. This method of genetic engineering, manipulation of DNA, is called 
recombinant DNA (rDNA). This transgenic methodology has now been applied to many other 
organisms such as fungi, mice, plants, pigs, sheep, fish, and even cows. Recombinant technology 
may be used to better understand human illnesses (as with Alzheimer’s mouse) or even to have 
animals produce essential life saving drugs by inserting genes encoding pharmaceutical enzymes 
into an animal genome. This technology is the first step in cloning genes. 
 Recombinant DNA technology allows for short specific portions of DNA to be inserted 
into a vector which aids the DNA amplification. Plasmids are commonly used as vectors since 
they are easy to manipulate.  Plasmids are molecules of DNA that are found in bacteria but occur 
separately from the bacterial chromosome (Figure-2). Plasmids are small, circular, and usually 
carry only few genes. The inserted DNA (shown as blue in the figure) replicates in the plasmid's 
cytoplasm, so a large number of DNA copies are created. The DNA may then be purified from 
the bacteria, and inserted into the host animal. 
 
 
 
 
 
 
 
 
 
 
Figure-2:  Diagram of DNA Cloning 
into a Plasmid.  Both plasmid DNA and 
the foreign DNA to be inserted into it are 
cut with restriction enzymes (upper part of 
diagram) to create complementary “sticky 
ends”.  The cut foreign and plasmid 
DNAs are then mixed (diagram center), 
and the foreign gene inserts in the proper 
orientation.  The joined DNAs are then 
treated with DNA ligase to seal the 
circularized the DNA into a functional 
plasmid (lower). (Introduction to Cloning 
and Biotechnology, 2005) 
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 Restriction enzymes are used to excise a piece of human DNA encoding the transgene 
(upper right in the figure). The restriction enzymes cut the DNA at specific sequences, and this 
allows the DNA to be inserted at the proper position in the vector. A ligase enzyme is then used 
to seal the two pieces of DNA together, creating the recombinant DNA molecule. To better 
understand this process, think of the restriction enzymes as enzymatic scissors for cutting the 
DNA, and the ligase enzyme as glue to hold the mixed DNAs in place. 
 
METHODS FOR CREATING TRANSGENIC ANIMALS 
 
Microinjection of DNA into the Male Pronucleus 
   
The method of DNA microinjection into the male pronucleus was the first successful 
transgenic technique utilized in mammals (mice in this case) (Wortman, 2000). Soon after, other 
species proved successful such as rats, cows, pigs, chickens, fish, birds, goats, and sheep. One of 
the benefits that contributes to the popularity of this microinjectionn technique is the variety of 
animals this can be applied to. Due to its success and reliability, pronuclear microinjection has 
become the most popular technique for making transgenic animals. 
 These transgenic animals are made by cloning the transgene of interest, and then inserting 
that gene into the genome of a newly fertilized egg. To do this, foreign DNA is inserted into an 
egg by using a microsyringe. The male pronucleus is usually used due to its larger size than the 
female pronucleus. The eggs are matured using hormone injections to increase amount of 
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ovulation in a group of animals. Once the eggs are harvested, they are injected with hundreds of 
copies of the desired DNA using a micropipette (Figure-3) (Transgenic Animals 2003). 
 
 
               
 
 
 
 
 When the microinjection procedure is successful, the animal will have the altered DNA 
in every cell of its body.  But this procedure is not always successful (Table 1), the larger the 
species, the less efficient the process. The process of DNA integration into host DNA is still very 
random. Where the transgene integrates into the host genome cannot be controlled, or sometimes 
the DNA doesn’t integrate at all.  In some cases, only some of the animal’s cells have the new 
DNA sequence, called a “mosaic animal”. The offspring of a “mosaic animal” will sometimes 
carry the gene and other times not. 
 
Animal Species Number of Ova Injected Number of Offspring 
Number of Transgenic 
Offspring 
rabbit 1907 218 (11.4%) 28 (1.5%) 
sheep 1032 73 (7.1%) 1 (0.1%) 
Pig 2035 192 (9.4%) 20 (1.0%) 
 
 
 
Figure-3: Microinjection of DNA into a 
Male Pronucleus.  The glass micropipette (on 
the right) is inserting the transgene into the 
egg. The device on the left is a microtube 
suction device that holds the egg in place. 
(http://www.medecine.unige.ch/transgenese/m
icroinj.jpg) 
Table 1: The Low Eficiency of the Microinjection Method.  
Figures in parentheses denote percent efficiency compared to 
original number of ova injected.  (Transgenic Animals and 
Plants, 2005) 
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Microinjection of DNA into ES Cells 
  
A second technique for making transgenic animals places the transgene into embryonic 
stem (ES) cells. These ES cells are isolated from the inner cell mass of blastocysts prepared by in 
vitro fertilization (IVF).  ES cells are undifferentiated, which means they have not yet generated 
more specialized structures or protein characteristics. ES cells are able to renew themselves, and 
later develop into almost all major specialized cell types. So, if the transgene can be inserted into 
an ES cell, then that cell can be microinjected into a blastocyst, to create a transgenic embryo, 
which can be implanted into the host uterus to create a transgenic animal (Stem Cell Basics, 
2006). 
 The first step in this technique is to perform in vitro fertilization and culture the embryo 
for 5-6 days to obtain a blastocyst.  ES cells are then obtained from the blastocyst (Figure-4). To 
help prevent differentiation of the ES cells, the cells often co-cultured with an embryonic 
fibroblast feeder layer that produces leukemia inhibitory factor. The inner cell mass of the 
harvested embryos is retrieved from the blastocyst, co-cultured, and selected for those cells 
showing undifferentiated morphology to indicate their likelihood of pluripotency.  Then ES cells 
are allowed to grow and multiply.  Foreign DNA is introduced into the ES cells using any of a 
variety of techniques, such as electroporation, microinjection, viruses, or chemical transfection. 
This ES technique has been growing in popularity because of the variety of techniques that can 
be used for incorporating the transgene into ES cells. 
 Electroporation is a process that uses a pulse of high voltage to make cell membranes 
permeable to introduce new DNA  into the ES cells. An electric charge passes through a plate  
consisting of DNA layered on top of cells. DNA contains phosphate residues that cause the DNA 
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to have a negative charge, and this is attracted to positive electrodes. As soon as the DNA is 
absorbed into the cell, the DNA moves into the cytoplasm, and eventually enters the nucleus to 
integrate into the nuclear DNA (Taconic, 2003). The cells become immortal ES cell lines that 
can be grown to large quantities to be evaluated for transgene incorporation. Due to evaluation 
process, only ES cells that actively took up DNA are reimplanted. This process allows for higher 
efficiency of the process. The ES cells can now be injected into a blastocyst, and the embryo 
implanted to make the transgenic animal. 
 
 
 
 
 
 
 
 
 
 This technique may be highly effective, but ES cell culturing is still very difficult. The 
survival rate of ES-injected blastocysts is low. And there usually is no way to control the 
location of where the DNA integrates, except with specific types of viruses.  It is also hard to 
determine whether the implantation of the embryo into the uterus will be successful. According 
to tests, no more than one third of embryos will have successful implantation into the uterus 
(Transgenic Animals, 2003). 
 
Figure-4: Summary of the ES Method 
for Making a Transgenic  Animal. 
Cultured ES cells are transfected with the 
cloned transgene (upper left).  Cells are 
then injected into a blastocyst (upper 
right). The blastocyst is implanted into a 
foster mother to produce transgenic pups.  
(Genoway, 2003) 
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DNA Homologous Recombination 
  
An advantage of using ES cells to create transgenic animals is the use of homologous 
recombination.  Homologous recombination, or gene targeting, is a method for inserting the 
DNA  that has control over where it integrates in the host DNA. The DNA of the transgene 
attaches to a known portion of the host’s chromosome and then exchanges with it (Figure-5). 
Through genetic engineering, the transgene is inserted within the known cloned host gene. After 
the host cell incorporates the DNA, the flanking host DNA sequences recombine with their 
homologous sites in the host cellular DNA to incorporate the transgene into that location. The 
DNA is targeted to a specific location of the genome through this method (Bronson and 
Smithies, 1994). 
 
 
 
 
 
 
 
 
  
Figure-5: Summary of the Homologous 
Recombination Method for Making 
Transgenic Animals. 
The transgene (blue) is inserted within a 
cloned host gene (middle). When the 
DNA is introduced into a host ES cell, the 
DNA flanking the transgene recombines 
with host cell  DNA to insert the 
transgene into a specific chromosomal 
location (bottom).  (Genoway, 2003) 
13 
 
DNA Viral Delivery 
 
 Viruses can also be used as a method for inserting foreign DNA into the ES cells. A 
retrovirus can be modified so that it carries the desired DNA sequence within the virus’ DNA. 
The disease causing genes in the virus are removed so they are not introduced into the transgenic 
animal. This allows the virus to infect the ES cells with a specific gene, but not cause disease. 
The germ line cells must be infected for this method to be successful. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-6: DNA Viral Delivery Method. 
Viruses can be used to deliver the 
transgene, and the genes causing the 
disease can be removed so the transgenic 
animals will not be introduced to them.  
(Cooper et al, 2000). 
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 The method of DNA viral delivery is effective, but not as efficient as desired. The size of 
the transgene sequence that can be added to the viral genome is limited. This method may yield 
mosaic animals, or interference with the expression of the transgene may occur. Animals created 
through this method often do not pass the transgene to their offspring. The offspring will receive 
a copy of the transgene only if the germ cells receive a copy of the transgene. 
 
Somatic Cell Nuclear Transfer 
 
The Somatic cell nuclear transfer (SCNT) is considered more efficient and safe when 
compared to the large number of embryos that are saved. During the process of SCNT, a nucleus 
is taken from a somatic cell and inserted with a transgene by use of microinjection. The nucleus 
then becomes reimplanted in an enucleated egg. Several days later the egg develops into a 
blastocyst, and is then implanted into a foster mother. Because the newly implanted nucleus 
already has the transgene in its genome, the offspring is certain to be a transgenic animal. 
 
 
 
 
 
 
 
 
 
15 
 
 
 
 
 
 
ASSAYS FOR SCREENING TRANSGENIC ANIMALS 
 
Southern Blot Test 
  
The Southern Blot test is a way to analyze the genetic patterns within DNA. This 
technique is utilized in the transgenic offspring before it passes six weeks of age. This test can be 
used in several ways such as to determine the number of copies of the transgene integrated, the 
number of chromosomal sites the transgene was inserted into, to validate the status of the 
transgene, and to determine if the transgene was intact. When scientists select which transgenic 
animals are to be used for breeding, they usually look for the transgenic animals that have at least 
five to ten copies of an intact transgene in a single insertion site (Brinton and Lieberman, 2007). 
 Transgenes usually insert in a head-to-tail position. Due to this, scientists carefully 
choose a restriction enzyme that will cut once in a transgene to release DNA fragments that are 
the same in size as the transgenes from the multicopy concatemer. Through electrophoresis, 
these DNA fragments are sorted by size. The DNA is then loaded on a gel (agarose) and an 
electrical charge is then passed through the gel. The DNA is attracted toward the positive 
electrode since it is slightly negative. The smaller fragments move quicker to the bottom, leaving 
the larger fragments toward the top. The DNA is brought to single stranded form by heating or 
Figure-7: Summary of the SCNT Method for Making a Transgenic Animal. 
Skin cells are removed from donor animal (upper left). The nucleus extracted (upper 
center) and injected with transgene.  The nucleus is injected into an enucleated egg 
(center) and that is implanted into a surrogate mother (Kae, 2003).   (Picture from 
http://www.biotechnologyonline.gov.au/images/contentpages/scnt.gif) 
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chemically treating the DNA in the gel. The DNA is now free to be hybridized with a probe 
DNA. The DNA in the gel is blotted to a membrane that retains the original DNA size pattern, 
while still allowing the hybridization probe to illuminate the transgene. The presence of a band 
hybridizing to the transgene probe indicates the transgene incorporated into the host DNA 
(Brinton and Lieberman, 2007). 
 
Western Blot Test 
  
Another method for screening transgenic animals is the Western Blot test.  Proteins made 
from the transgene are detected using antibodies directed against the transgene protein. This is 
similar to the Southern Blot test except protein extracts are electrophoresed and blotted to the 
membrane instead of DNA, and then the antibody detects the trans-protein on the blot. When the 
trans-protein is being made in the cells from which the lysate was made, then it will be 
represented by a band on the gel (Western Blot Activity, 1998). 
 
Enzyme Linked Immunoabsorbent Assay (ELISA) 
  
ELISA is another technique for detecting the presence of transgenic proteins. The ELISA 
technique and Western Blot test both measure the cellular levels of a specific trans-protein. The 
Elisa technique is more quantitative.  This technique is used to measure the amount of trans-
protein found in sample of blood, urine, and animal serums. The first step uses a plastic tray with 
wells. These wells are coated with a particular antibody that binds to transprotein present in the 
added lysate.  After washing un-bound protein out of the well, a detecting antibody is then added 
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to detect the captured trans-protein. The greater the concentration of transprotein present in the 
lysate, the greater the colored signal in the well (ELISA Activity, 1998). 
 
Real Time RT-PCR 
  
Real Time RT(Reverse Transcriptase)-PCR is used to screen for the expression of the 
transgene. This technique detects mRNA encoding the trans-protein. A tissue (brain, pancreas, 
liver) is removed and the mRNA in the cytoplasm is extracted.  Reverse transcription is 
performed to synthesize DNA from the mRNA.  The DNA is then amplified using a specific set 
of primers designed to amplify the trans-gene using fluorescent primers.  The mRNA that was 
converted into cDNA is visualized by increased fluorescence into polymer. The Real Time PCR 
method is useful in proving the expression of the transgene and proves that the DNA sequence of 
the transgene is being transcribed and expressed (Hunt, 2006).  
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Chapter 2: Transgenic Animal Classifications and Examples 
 
 This chapter will show examples of each class of transgenic animal, focusing on their benefit to 
society as an introduction to a discussion of transgenic ethics in Chapter-3.  Before we can discuss the 
balance between benefit to society versus detriment to the animal, we need to have an understanding as to 
why these animals were made.  These animals were created as a way to provide better medicine and 
science, better sources of medicines, alternative source of transplant organs, or alternative food sources.  
Transgenic animals can roughly be divided into five classes:  Disease Models, Transpharmers, 
Xenoplanters, Food Sources, and Scientific Models.   
 
Disease Models 
Transgenic disease models are animals that have been genetically altered and 
manipulated to acquire a particular human disease, or to acquire a small portion of a human 
disease.  This is done so that scientists may study the disease without jeopardizing human life.  
The study of these animals can lead to a better understanding of how each condition develops 
and progresses and, through testing, can possibly lead to a cure.  Since animals and humans are 
not identical, it is necessary to alter the subjects through the use of a transplanted gene that 
stimulates the onset of a human disease.  This manipulation allows the disease in the animal to 
progress similarly to the way it would in humans.  Once this process is completed, the animal 
can be observed and tested under conditions that could be harmful to humans.  Once a successful 
therapeutic agent has been identified, that drug is then tested in human cells in vitro, then in  
human clinical trials.  However, there are still many ethical dilemmas that go along with creating 
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diseases in transgenic animals.  Examples of transgenic disease models are Huntington’s 
Monkey, AIDS mouse, Alzheimer’s mouse, and Parkinson’s fly  
 
Huntington’s Monkey 
 The most recent breakthrough in transgenic disease models is the Huntington’s monkey.  
Huntington’s disease is an inherited defective gene that can trigger certain nerve cells in the brain to die.  
It affects five to ten people in every 100,000, and it is fatal with death normally occurring 15 to 20 years 
after onset.  The research team which initially developed the macaque monkey model did so by 
introducing altered forms of the Huntington gene into macaque eggs with a viral vector. The altered eggs 
were then fertilized and the embryos were implanted into a surrogate primate mother.  The result was the 
birth of 5 live monkeys, providing the world’s first “rhesus macaque model of a specific human disease 
using transgenic technologies, and providing a marked improvement over the previous mouse models” 
(Researchers Develop…, 2008).  Because the rhesus macaque monkeys come much closer to resembling 
human make up than mice, these models will help scientists to understand more about this disease in 
humans. 
 
AIDS Mouse 
 While monkeys are sometimes used as disease models due to their close physiology with humans, 
they are rather expensive to purchase and maintain.  Mice are very popular for transgenic experiments due 
to their ease of experimental manipulation, and short generation times, and in 2004 researchers developed 
a very useful mouse called AIDS mouse.  Like the Huntington’s monkey, researchers injected newly 
fertilized mouse eggs with the AIDS provirus DNA.  The manipulated eggs were then removed and 
implanted into a surrogate female mouse (Bunce and Hunt, 2004).  AIDS is considered to be the greatest 
epidemic the world has ever seen and these mice are helping to find a cure for the disease.  HIV, Human 
Immunodeficiency Virus, attacks human cells presenting CD4 and chemokine receptors on their 
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surfaces. The virus maneuvers itself inside these cells at which point it begins to replicate and, 
when CD4-T-cell  levels drop dramatically, the disease becomes AIDS (Bunce and Hunt, 2004).  
AIDS disease is characterized by malignancies, problems in lymph node tissues, skin lesions, 
and cellular and immune irregularities (Kohn, 2001).  There is no current cure for those with 
HIV/AIDS, however, with proper treatment, infected persons can slow progression of the virus. 
 
Alzheimer’s Mouse 
Created in part here, at WPI (Games et al., 1995), this transgenic animal mimics the 
symptoms of an Alzheimer’s patient.  Alzheimer’s disease (AD) is a neurological disorder 
affecting memory.  AD is associated with highly neurotoxic β-amyloid synthesis and deposits in 
the hippocampus and cerebral cortex.  For most patients, the onset of AD occurs late in life, in 
the mid-70’s.  However, some people have DNA mutations in the amyloid precursor protein 
(APP) gene which accelerate the production of toxic β-amyloid, so families with this mutation 
often get early onset AD in their mid-40’s.  Over time, these β-amyloid proteins aggregate senile 
plaques, one of the pathological hallmarks of AD.   
The world’s first Alzheimer’s mouse (Games et al., 1995) was engineered to contain an 
APP mutation that mimics an Indiana family with early onset AD.  The production of toxic β-
amyloid occurred in the same areas of their brains as with AD patients, and its production caused 
neurodegeneration (Duff et al, 1996).  This mouse model has since been used by Elan 
Pharmaceuticals to create the first AD vaccine, an antibody against β-amyloid (Schenk et al., 
1999).  The vaccine in mice proved very effective, virtually eliminating the creation of newly 
formed amyloid plaques in young mice and reducing mature plaques in older mice (Schenk et al, 
1999).  However,when Elan moved on to human clinical trials, the vaccine was effective at 
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removing β-amyloid, but “autopsies on seven patients who died of Alzheimer's during the study 
showed that nearly all of the sticky β-amyloid protein…had been removed, but all patients still 
had severe dementia” (Alzheimer’s vaccine…2008).  Elan has recently initiated a second clinical 
trial with a slightly different vaccine that, through clinical Phase-II, appears safe.  
 
Parkinson’s Fly 
Parkinson’s disease (PD) is a neurodegenerative disorder that affects the central nervous 
system, especially the substantia nigra which is an area of the brain that produces dopamine.  
Symptoms of the disease usually include tremor, muscular rigidity, and slowed physical 
movement.  In 1997, scientists found the first genetic link to the disease, a mutation in the α-
synuclein gene which may lead to a lack of dopamine (Vogel, 2000).  The ability to monitor the 
α-synuclein gene in fruit flies has given scientists the ability to monitor the disease throughout its 
course, whereas in humans symptoms are not usually visible until approximately 60-80 percent 
of dopamine nerve cells have become damaged or destroyed (Vatalaro, 2000).   
Scientists at Harvard Medical School have created three types of transgenic flies that 
express different versions of the human α-synuclein gene.  “In all three strains, the dopamine-
producing neurons--the same ones that die in human Parkinson's disease--die off in adult flies... 
In addition, the neurons form… abnormal accumulations of protein that include high levels of 
the α-synuclein protein” (Vogel, 2000).  The death of the dopamine neurons leads to the flies’ 
inability to climb walls, whereas their normal counterparts have no problem with this feat.   
The ability to reproduce the symptoms of Parkinson’s disease in flies is not only a great 
way to study the disease, but it is also extremely cost effective.  This model, although seemingly 
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very different from mankind, could be a very good way of finding a cure for this degenerative 
disease in humans. 
 
Transpharmers 
Transpharmers are genetically engineered animals that produce specidic compounds in 
their milk, saliva, urine, or blood.  While expression in any of these four locations can be 
achieved, it is most commonly engineered for expression in milk.  The idea is to specifically 
mutate the DNA of the animal so that it secretes a pharmaceutical drug “naturally” into the milk.  
This type of transgenic animal is probably the least debated genetic altering done to animals 
because there is no harm done to the animal, its milk is simply harvested to obtain the drug.  
Normally, scientists first test the method on mice before moving to larger farm animals, since the 
process is technically more difficult in larger animals.  This is to ensure that the process is 
successful before moving on to the more expensive, more difficult livestock.  Transpharming has 
already been successful, yielding several useful pharmaceutical compounds and proteins in cows, 
pigs, sheep, and chickens (Gillespie, 2005).   
One such example is named Herman the Bull.  This bull was created by microinjecting 
cells with the gene encoding lactoferrin during the early embryo stage.  Once cultured, these 
manipulated embryos were transplanted into recipient cows.  The only transgenic calf was 
Herman, a male.  Herman was subsequently bred and his female offspring transpharmed 
lactoferrin in their milk (Biotech Notes, 1994).  This process could result in the production and 
sale of an alternative version of milk.  Lactoferrin is an iron-containing protein that is necessary 
for the growth of infants.  By adding this to milk, it is now possible to create a milk that is 
suitable for infant growth.  It was thought that the new protein-enhanced milk could help to feed 
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infants in developing nations.  Unfortunately, Herman’s offspring, while producing lactoferrin in 
their milk, did not produce enough of it for the milk to be commercially worthwhile, and the 
product never made it to market.  While this lactoferrin example did not pan out, the same 
technology can be used to transpharm other proteins that can be purified and possibly marketed. 
Another example of a transpharmer came in 1997 when scientists at the Roslin Institute 
generated six transpharmer sheep.  Each of these sheep secreted a blood clotting agent in their 
milk that is found in humans (Schneike et al, 1997).  In 1999, scientists created another form of 
tranpharmer goat which expressed high levels of antithrobin III, a chemical that acts as an 
anticoagulant in humans.  These goats were created using a new process known as SCNT, 
somatic cell nuclear transfer (Figure-1).  In this process, a nucleus of an adult somatic cell is 
removed and transplanted into an enucleated egg.   The egg containing the somatic cell is then 
stimulated to divide, and it is grown to the blastocyst stage then implanted into a surrogate 
mother (“Somatic cell…”, 2002).   
 
 
Figure 1: Diagram of Somatic Cell Nuclear Transfer.   Tissue is donated from an adult 
(upper left).  The nucleus is extracted and injected (center) into an enucleated egg (lower 
center).  The embryo is grown to the blastocyst stage, then implanted (Diagram right). 
From: www.biotechnologyonline.gov.au/.../img_scnt.cfm 
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While this SCNT procedure provides a way of creating transgenic animals from adult 
nuclei, the process has a low success rate.  Regardless, creating transpharmers is a non-painful 
way to create a desired pharmaceutical in an animal that can continue to produce it at low cost. 
 
Xenoplanters 
 Xenoplanters, or Xenotransplanters, are animals that have been genetically modified so  
their organs may be successfully transplanted into humans.  The act of harvesting an organ from 
one species and implanting it into a different species is called a xenotransplant.  Although this 
process normally causes immunorejection of the organ,  xenoplanters are engineered so they do 
not express key foreign antigens to avoid causing immunorejection.  Due to our current lack of 
organ donors, xenotransplantation could develop into a great way for humans to receive donor 
organs to last them until human organs become available.   
However, not all of the problems have been worked out, and most xenotransplants have 
failed.  Yet there is still much hope surrounding this technology.  Several xenotransplants have 
been attempted with varying response, mostly negative.  In 1984, doctors at the Loma Linda 
University Medical Center in California attempted a xenotransplant that involved transplanting 
the heart of a baboon into an infant child.  Baby Fae, as she became known (Figure-2), was born 
with a fatal heart defect known as hypoplastic left heart.  At first the transplant looked to be a 
success, and doctors were pleased with the progress she was making, but two weeks after the 
implant, heart complications arose and the infant’s body began to reject the heart.  Baby Fae died 
three weeks after receiving the heart (Wallis, 1984).   
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Figure 2:  Picture of Baby Fae After Receiving her 
Xenotransplanted Heart from a Female Baboon.  Credit: Loma 
Linda University Medical Center.  From: 
http://www.sciencemag.org/cgi/content/full/295/5557/1008/F1 
 
Other examples involving the transplant of primate organs into humans have occurred, 
but no person receiving a xenotransplant has lived for more than 9 months.  Although these 
results do not have the type of outcomes scientists and doctors strive for, they are huge steps in 
the right direction for the process of xenotransplantation. 
 More recently, scientists have turned to pigs as the main source of xenotransplants.  
While primates have very similar genomes to humans, size differences limit the number of 
patients who can receive the organs.  Because a pig’s physiology is quite similar to that of our 
own, researchers have attempted to figure ways to engineer them so successful xenotransplants 
can occur.  The problem that exists with pig organs is the hyperacute rejection that occurs when 
human antibodies come in contact with the surface of the porcine organ cells (Couzin, 2002).  A 
gene in pigs codes for an enzyme known as alpha-1, 3-galactosyltransferase which is an enzyme 
that adds the sugar alpha1, 3-galactose to the cell surface.  When human antibodies come in 
contact with these sugars, which riddle the surface of pigs’ cells, it is viewed as foreign, leading 
to hyperacute rejection (Pearson, 2003).  In order to avoid this, scientists have experimented with 
avoiding the entire transplant of the organ and attempted to use individual porcine cells to treat 
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the patient intravenously.  At several hospitals in countries around the world, doctors have taken 
patients with acute liver disease and hooked them up a machine that treats their blood with 
porcine liver cells.  Circe Biomedical of Lexington, Massachusetts conducted a study of 171 of 
these patients.  While the procedure did not result in a cure, it did prolong the survival of a 
majority of patients, giving each more time to find a human donor (Couzin, 2002). 
 Although physical xenotransplantation of animal organs has not been nearly perfected, 
there is hope that it may one day be a viable option to patients in need.  The use of porcine cells, 
however, does seem to be a procedure that could help to save lives.  With time we will determine 
whether or not xenotransplantation of organs can be successful, but until then, animal cell 
therapy seems to be the best option when a human donor cannot be found.  
 
Food Sources 
 This classification of transgenic animal is used, as its name implies, as a food source for 
humans.  These animals are genetically altered to increase the food supply by maturing in less 
time and using fewer resources to achieve larger growth.  An example of this is when a growth 
hormone is applied to a particular animal’s genome.  This results in a “super” animal that has 
several advantages over the same animal without the applied hormone.  Examples of this are 
“Superfish” and “Flavr Savr”. 
 
Superfish 
 In Vancouver, British Columbia, scientists at the federal Fisheries and Oceans Canada 
research lab have been experimenting with salmon.  They have taken normal coho salmon and 
inserted an extra growth hormone gene from the sockeye salmon.  These coho salmon (Figure-3) 
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grow approximately four times faster than coho salmon without the inserted gene.  By 
microinjection of the sockeye growth hormone gene into a newly fertilized coho salmon egg, a 
coho fish containing the combined genes is produced.  In this case, the result is a faster growing, 
larger fish (Clarren, 2003). 
 
 
Figure 3: Photo of wild coho salmon (left) compared to transgenic 
coho salmon (right).  From http://www.hcn.org/issues/253/14058 
 
 First attempted in the late 1980’s and early 1990’s, by A/F Protein Inc. of Massachusetts, 
the superfish technique was used to create fast-growing fish to counteract the dwindling number 
of wild cod and salmon on the East Coast.  Since then, the practice has become rather 
commonplace, but not without controversy.  Because wild salmon have natural instinct that are 
lacking in the pen-raised, transgenic salmon, there are issues with the problem of breeding 
between the two.  In a computer model created at Purdue University, researchers found that 60 
transgenic fish released into a population of 60,000 wild fish, would take just 40 fish generations 
for the the wild species to become extinct (Clarren, 2003).  This could be a very grave outcome 
but, if properly monitored, these transgenic fish could become a staple of every person’s diet, 
also helping to feed those who lack food elsewhere in the world. 
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Flavr Savr 
 This transgenic food source, known as the Flavr Savr was one of the first transgenic 
foods to be FDA approved.  Flavr Savr is aptly named because it is a tomato that ripens slower 
than conventional tomatoes to stay on the vine longer.  It was created through a process known 
as antisense technology, in which RNA complementary to the mRNA that encodes a specific 
gene is expressed in a cell.  The complementary RNA binds to the mRNA inactivating it, thus 
reducing the amount of protein it encodes.  This procedure was used to knock down expression 
of the enzyme polygalacturonase which is necessary for the synthesis of ethylene.  Ethylene 
breaks down pectin to initiate ripening in normal tomatoes.  Producing less polygalacturonase 
leads to a slower ripening.  In the case of the Flavr Savr, it can be picked from the vine red and 
remain that way for several weeks until it starts to go bad (Krimsky and Murphy, 2002).  The 
Flavr Savr tomato was the first genetically modified whole food to be marketed to consumers in 
the United States. 
 
Biological Models 
 Transgenic biological models are genetically engineered to teach us something about the 
function of a particular protein in vivo.  Specific proteins can either be over-expressed or under-
expressed (knocked out), and its effects observed on multiple systems in the body.  Having 
already taught us a great deal about genetics and biology, the goal of these models is to continue 
this expansion of knowledge through the use of transgenic scientific models.  Two such 
examples are Smart mouse and ANDi. 
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Smart Mouse 
 In 1999, researchers at Princeton University genetically engineered a mouse to over-
express gene NR2B.  This gene is essential to the brain’s ability to associate one event to 
another, a basic feature of learning, especially in young animals.  When studying mice that 
lacked the NR2B gene, researchers found that these mice had learning impairments and poor 
memory.  NR2B has proved to be so essential because it is a key subunit of the NMDA receptor.  
NMDA acts as a receptor in the brain and is an excellent tool for creating memory.  While 
experimenting, researchers not only gave mice extra NR2B genes but they engineered them to 
increase NR2B activity with age.  This resulted in mice with a far greater learning response than 
those without the extra gene, so they were called Smart Mice.  Moreover, the mice with the 
NR2B gene retained brain activity normally specific to adolescent mice even after the Smart 
Mice aged (Harmon, 1999).  This finding helps prove the hypothesis that NR2B protein 
functions to provide a more efficient firing of the NMDA receptor, as occurs naturally in young 
animals.  “The finding also shows that genetic improvement of intelligence and memory in 
mammals is now feasible, thus offering a striking example of how genetic technology may affect 
mankind and society in the next century” (Harmon, 1999).  To know that genetic improvement is 
possible in animals is a huge breakthrough and it is certain that much will be done in an attempt 
to convey similar results in humans. 
 
ANDi 
 In an attempt to create the first transgenic primate, researchers at the Oregon Regional 
Primate Research Center injected a genetically modified virus into an unfertilized rhesus monkey 
egg.  The egg was then fertilized and implanted into a surrogate mother.  Although this was done 
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to several eggs at the same time, many of which failed, it did result in one success.  ANDi, which 
stands for inserted DNA spelled backwards, was born with the foreign gene encoding green 
fluorescent protein (GFP).  While gene transfer is rather commonplace in other species, this is 
the first demonstration that the manipulation of a primate egg can result in a successful birth.  
The GFP, extracted from jelly fish, is present in ANDi cells, but does not have the same affect 
that it does on jelly fish (Vogel, 2001).   
 
Figure 4: ANDi, the first transgenic primate contains the green 
fluorescent protein.  From: 
http://www.sciencemag.org/cgi/content/full/291/5502/226a/F1 
 
While the idea of a green monkey is rather useless, the fact that scientist have been able to create 
a genetically altered primate is fantastic, as it opens the door for testing the function of other 
specific proteins in a model similar to humans.  Although smaller subjects with less compatible 
physiology such as mice and rats are useful, primates, unlike mice, are able to fit in magnetic 
resonance imaging machines.  This could lead to researchers using such machines to track organ 
development without hurting any primate.  Ideally, transgenic primates, with their similar 
physiology to humans, could do great things for the advancement of science and medicine.   
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Chapter Conclusion 
This chapter attempts to provide a background on the success of transgenic research to 
allow subsequent comparisons of their benefit to society versus detriment to the animal in 
Chapter-3.  Although it does not go into every aspect of transgenic animal research, it is meant to 
form a basic understanding on the topic of transgenics and the main categories of animals formed 
to date.  While still hotly debated, transgenic animals have led to a far greater understanding of 
diseases and medical conditions.  The medical wonders that have developed from xenoplanters, 
disease models, and transpharmers could lead to cures for countless diseases.  Food source 
transgenic animals could help feed those in need.  And biological transgenic models are helping 
us learn more about the functions of specific proteins in vivo.  If practiced humanly, transgenic 
animals could have an even more profound effect on human life. 
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Chapter-3:  Transgenic Ethics 
 
 In today’s world, as discussed in Chapter-2, transgenic animals have the ability to 
contribute to scientific and medical advancement in a big way.  However, their benefit to society 
is not the only thing to consider with this new technology; ethical and moral issues arise with the 
creation and modification of life.  In an age where scientists’ capabilities to manipulate life seem 
endless, it is important to decide what boundaries will be set.  In order to do this, we must 
carefully weigh all the advantages and disadvantages of this technology. We must take into 
account the concerns of many different public sources, including different cultural and religious 
backgrounds.  We must also take into account which types of these new animals would be 
acceptable with regards to ethics, requiring a discussion of the amount the animal suffers versus 
the medical benefits gained.  In some cases there is barely any animal suffering with great 
benefit to society, while in others the suffering is severe. So where do we draw the line? 
 
Concerns of Transgenics 
  
 Probably the biggest concern would be the treatment of the animals. How much do the 
animals suffer during these experiments? Are scientists making sure that they suffer as little as is 
needed to carry out the research, or are they treating them as objects and not drawing the line at 
any particular point?  Then there come the cries that scientists have no right to do the research in 
the first place. Many animal rights groups and environmentalists believe that it is wrong to alter 
and potentially harm any animal’s genetics. Then there is also the concern of where transgenics 
stops.  Will transgenics carry over to humans? Will we begin to alter the genes of humans and 
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ultimately end up playing God?  Some would say that it’s not about playing God but creating 
better life for people. Humans have always made engineering advancements with the intention of 
improving life. Isn’t this just another one of those instances? 
 Why all of a sudden is there an out cry from the public that transgenics is unethical; that 
it is a way for scientists to play God.  But, hasn’t similar events been taking place for many years 
now. Take the farming industry for example.  Farmers have been using breeding techniques for 
generations in order to grow stronger animals faster than ever before. The faster these animals 
are grown, the more food there is to feed the world. Yet, this is not considered wrong and 
transgenics is. Isn’t transgenics just picking up where selective breeding let off?  If this is true, 
then why aren’t both considered unethical?  
 As previously stated, the largest concern from the public is the treatment of the animals. 
Many are against any kind of suffering that may occur, but not everyone has the same ethical 
views.  Most animal rights groups tend to have a Kantian point of view, in which they believe 
that an action can only be right or wrong in and of itself.  In this case, our actions of making an 
animal suffer, by itself as an action is considered wrong.  On the other hand, scientists and 
researchers adopt a utilitarian point of view in which the action can be considered good or bad 
based on the results which it produces. Therefore, it is not necessarily wrong for an animal to 
suffer, as long as the amount of human suffering the research stops outweighs the amount of 
suffering which occurred during the research. A perfect example of this would be AIDS mouse. 
The research done on these mice has helped scientist learn more about a disease that has killed 
countless people.  How can the sacrifice of these mice have been considered immoral?  
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Benefits of Transgenics  
 People can scream immoral all they want, but they must take into account all the societal 
benefits of transgenics. These benefits are seen in the food industries, as well as the medical 
world.  Medically, transgenics is working wonders. Animals such as xenotransplanters, AIDs 
mouse, Alzheimer’s mouse, smart mouse, youth mouse, and oncomouse all make huge 
contributions to the medical field.  Xenotransplanters are helping bring about the technology for 
transplanting animal organs into humans. The disease mice are helping to find a cure for AIDs, 
Alzheimer’s, and certain cancers. The smart and youth mice are helping scientists make human 
improvements in the areas of memory and heart disease.  
 In the world of agriculture, benefits are seen with the creation of transgenic plants that are 
disease resistant, and some transgenic animal food sources (especially superfish) that can be 
grown larger and faster on less food, making more food readily available for the world.  All of 
these advantages of transgenics must be talent into account before condemning it. 
 
Oncomouse 
Oncomouse is a perfect example of how close to the ethical line a transgenic animal can 
come.  This is one of the most widely disputed cases.  As discussed in Chapter-2, this mouse was 
created  in the early 1980’s when Harvard medical researchers genetically modified a mouse to 
include a human oncogene, which can cause the growth of tumors. This mouse was going to 
allow them to greatly increase their knowledge of cancer, so Harvard and Dupont decided to get 
a patent for their new creation in the U.S. and many other countries.  
This case was met with many ethical dilemmas. Of the questions raised, the two most 
important questions were as: should animals be able to be patented? And what will the new 
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moral limits be in this case?  Think of it what it would mean to have a patent on an animal. That 
would mean it was your property and would totally objectify it.  
Although the patent was eventually awarded in the U.S., when Harvard applied for the 
patents in different countries, they were met with different attitudes.  The European Patent Office 
also granted Harvard a patent, but using different reasoning. They decided that, while it would 
not be alright to patent an animal variety, oncomouse was not an animal variety and was 
therefore permissable. They further applied a utilitarian test, they took a look at how much the 
mice would suffer and weighed it against the benefits it would produce for mankind, and decided 
the the benefits exceeded the harm to the mice.  
Years later, the European Patent office came across a very similar case.  Upjohn 
Pharmaceutical company created a transgenic mouse that would lose it’s hair. The purpose was 
find a cure for human baldness. The EPO again applied the utilitarian test and ruled the opposite 
of oncomouse. They again weighed the suffering of the mice against the beneifts of the research 
and decided that benefits would not be great enough to outweigh the suffering.  They thus 
decided it would be immoral to patent such a creature. 
 Canada had some mixed feelings when it came to oncomouse. At first they used the 
definition of patentable materials as a reason for rejecting Harvards new creation. Under their 
patent laws, the object being patented must be a “manufacture or composition of matter.” They 
realized that while the oncogene injected into the mouse was a mixture of ingredients and 
therefore patentable, the body of the mouse was not.  However, later rulings found that the 
invention that went into the mouse altered it, so Oncomouse represents an animal no longer 
found in nature, and it was thus a “composition” of matter and therefore patentable.   But later 
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Canadian Supreme Court rulings denied the patent.  The legal aspects of this case will be 
discussed in Chapter-4. 
 
Superpig 
 
Another interesting case to look at is Superpig. Superpig was created by injecting a pig 
with a transgene for growth hormone. This boost in growth hormone was supposed to produce 
leaner meat and allow the pig to grow much faster. This would mean there would be an increase 
in pork production and more people would have food.  However, the problem with Superpig is 
the amount that it suffers because of this growth hormone; there were many health problems, 
including  arthritis, and eventually multiple systems failure including heart complications, 
pneumonia, and kidney disease.  Even the scientists felt that the creation of such an animal was 
wrong, so they euthanized the pigs and placed a voluntary moratorium on any other further 
research that involved animals and growth hormone.  
 
Alzheimer’s Mouse  
 
Unlike the previous examples, Alzheimer’s mouse is a type of a transgenic animal that 
does not appear to suffer.  Created in part here at WPI, by injecting a mouse with β-amyloid 
gene, the mouse develops some of the symptoms of Alzheimer’s disease (Games et al., 1995).  
By researching this mouse, scientists will better understand the pathology of the disease.  In fact 
one of the major societal benefits of this mouse was the development of the world’s first 
Alzheimer’s vaccine that clears out β-amyloid and senile plaques (Schenk et al., 1998).  One of 
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the major questions these mice answered was whether β-amyloid and the senile plaques it 
eventually forms, are the cause of Alzheimer’s disease, or a side effect. This mouse proved that 
β-amyloid synthesis by itself is sufficient to initiate the disease (Games et al., 1995).  As stated 
before, the mice do not suffer during the research which makes this a wonderful technology. The 
only problems they have are with memory and learning, but this does not cause the any pain.  
 
Transgenic Fish 
 Transgenic fish are yet another species in which scientists make genetic alterations. By 
injecting the fish with genes that boost growth hormone, as in the superpig case, the fish are able 
to grow larger and faster than domestic fish. Unlike superpig though, these fish do not show the 
same adverse side effects.   So in this case they do not appear to suffer, but problems could arise 
if they escape into the environment and out compete native fish. 
 Transgenic fish have to be kept isolated from natural fish. They could not be allowed into 
nature because at the speed at which they can grow and reproduce, they would totally disrupt the 
natural balance, consuming all resources.  So these fish must be carefully regulated. 
 
Religious Views of Transgenic Animals 
When it comes to transgenic animals, religion appears to have mixed feelings on the 
subject. The problem is there are not clear guidelines regarding the manipulation of animals. 
It all depends on how you interpret each religion. Take Christianity for instance. There are 
many arguments against transgenic animals. Some say that God created man and animals in a 
certain way and to tamper with that would be a sin. On the other hand, there are others who 
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say that human beings have been given “dominion” over all animals, and they are entitled to 
do with them as they please. 
Other religions such as Buddhism, and especially Hinduism, hold animals sacred. 
Hindus believe that all living creatures are sacred and have many animal representations for 
their gods. On the other end of the spectrum there are the Muslims. The Muslim religion 
believes in animal sacrifice and is all for transgenic animals, as long as it benefits mankind.  
 
Chapter-3 Conclusions 
 Judging from the material presented in this chapter, one can see that this topic presents 
quite an ethical dilemma.  The chapter presented many of the benefits to society of these 
animals, including larger amounts of food, better knowledge of diseases, and possible organ 
donors for patients awaiting transplants.  But these benefits must be weighed against the 
potential for animal suffering, and the tampering with nature.  Transgenic animals such as 
superpig and oncomouse undergo huge amounts of suffering in order to produce those 
benefits, while others such as transgenic fish and Alzheimer’s mouse do not.  So we conclude 
that transgenics as a whole must be broken down into specific situations, and each experiment 
weighed by itself.  Even looking at the major religions which have been around for centuries 
one can see that it is hard to arrive at one clear cut answer.  
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Chapter-4: Patentability Issues with Transgenics 
 
 The United States patenting process in itself is very difficult, and when applied to the 
issue of patenting life, things become even more complicated.  After all, the purpose of a patent 
as described in the case of Warner Jenkinson v. Hilton Davis Company, is as follows “ The 
patent law is directed to the public purposes of fostering technological progress, investment in 
research and development, capital formation, entrepreneurship, innovation, natural strength and 
international competitiveness.” (“Warner Jenkinson Co...”, 1997).  The goal of patenting, and 
the guidelines within it, allow the introduction of new technologies that will benefit society. The 
main question in the patentability of transgenics is who, if anyone, has the right to patent life. In 
order to patent an invention, according to the United States Patent and Trade Office, the 
invention must meet three requirements.  A product must have proven novelty, utility and non-
obviousness.  But if one can apply all three of these criteria to a patent on life, should it still be 
granted?  In this chapter these questions will be explored through several historical cases, and by 
taking a look at  the benefits and drawbacks of patenting life. 
 
Diamond Vs. Chakrabarty (1980) 
 
 In 1793, Thomas Jefferson wrote that a patentable object was “…any new and useful art, 
machine, manufacture, or composition of matter, and any new and useful improvement on any 
art, machine, manufacture, or composition of matter”(“A Brief History of the Patent Law…”, 
2003).  The phrase that has caused the most controversy in the quote above is “composition of 
matter” and what exactly does it constitute. Everything in our world is a composition of matter, 
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from oceans, to mountains, and even life-forms.  Biotechnology, which can be defined as the 
study and “…use of microorganisms to perform specific industrial processes” (WordNet® 3.0, 
2008), constantly deals with the composition of matter, which some consider living breathing 
organisms.  Initially composition of matter was not considered “life”, but one of the first cases to 
challenge that interpretation was Diamond Vs. Chakrabarty. 
In 1972, Dr. Ananda M. Chakrabarty discovered a new way to break down crude oil with 
a created bacterium.  By introducing two plasmid DNA’s into the gene structure of a 
pseudomonas strain of bacteria, Chakrabarty invented not only a new organism, but a new 
technology that could be used to benefit man and the environment. Its main benefit was found in 
its ability to assist in the clean up of catastrophic oil spills. 
 
 
 
Figure-1:  Photo of Dr. Ananda Chakrabarty. 
 
 
 
 
 
 Chakrabarty’s first attempt at a U.S. patent with the General Electric Company had all 
but one of three claims filed accepted.  The two claims that passed were for a method of 
producing bacteria, the second was for a carrier which existed in a material floating on water.  
The third claim was rejected because it was considered a claim for patenting “a product of 
44 
 
nature”, was for the bacteria itself.  This was no surprise to Chakrabarty, for this was an attempt 
to patent a living organism, which had never been done before.   
 Under the U.S. Patent and Trade Office, Chakrabarty’s filed patent did meet their three 
required criteria under section 101.  Its novelty was that at the time there was no organism in 
nature that could break down crude oil.  Its usefulness was its ability to assist in the clean up of 
oil spills, and its non-obviousness was actually quite obvious.  Dr. Chakrabarty was not going to 
give up so easily, with such a great invention and strong case to back it up.  Almost as soon as 
his patent was shot down, he appealed to the Supreme Court using The Plant act of 1930.  The 
Plant act gave a patent to asexual reproductive plants, living organisms.  This was just not 
enough of a case to get his patent approved.  The Patent Office Board of Appeals stated 35 
U.S.C. 101 was not originally intended to apply to living organisms.  The case was also outdated, 
and if he was to win the rights to his patent he needed a more recent case to support him.   
 
 
Figure-2:  Drawing of Dr. Ananda 
Chakrabarty.   
 
 
 
 In a different case, in 1977, a patent for a microorganism was finally granted to Malcolm 
E. Bergy.  In the case of Malcolm Bergy v. Lutrelle Parker,  the C.C.P.A. accepted Bergy’s 
application for a patent of a microorganism that helped create an antibiotic.  The Acting 
Commissioner of Patents and Trademarks stated that “the fact that the microorganisms are alive 
is without legal significance”.    
45 
 
Using this 1977 case as a precedent, this time around Chakrabarty had a better case, but it 
was still rejected based on pertinence.  Once more Chakrabarty battled back and asked for a 
remand, followed up by a writ of certiorari which allowed him to have his case reviewed by a 
lower court and have his full case record reviewed.  Considering past court cases and 
interpretations, the Supreme Court in 1987 finally granted Chakrabarty his patent rights, to the 
method, the inoculum, and the patent to the micro-bacteria itself.  This created a new gateway in 
the field of transgenics with living organisms. 
 On April 21, 1987, seven years after the landmark case of Diamond Vs. Chakrabarty the 
Patent and Trade Office released this statement: “The Patent and Trademark Office now 
considers non-naturally occurring non-human multicellular living organisms, including animals, 
to be patentable subject matter within the scope of 35 U.S.C. 101”(Patent and Trademark Office 
Notice, 1987).  Thus, Biotechnology was given its first patented life, opening a new door to the 
world of transgenic research, which would continue to cause controversy even to this day. 
 
 
Events Leading to the First Animal Patents 
 
 Days before the 1987 ruling of Diamond vs. Chakraburty, on the 3rd of April, the courts 
had denied the case of Ex Parte Allen, which involved an attempt to patent a process to create 
edible oysters by exposing them to pressure.  It was struck down on the basis that the 
“multicellular animal involved was not a bar to patentability” (Woessner, 1999).  After the ruling 
on the 21st, the court needed to once again revise their findings to comply with their previous 
decision.  The Patent and Trade Office stated that they would accept “nonnaturally occurring 
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nonhuman multicellular living organisms, including animals.”  Through this statement they 
reiterated the fact that the obviousness of the patent was their main reason behind striking it 
down the first time, not because it was a multicellular organism.  With a firmer definition on 
patentable life, it wouldn’t be long before first animal patent was accepted.  
 
Harvard & DuPont’s Oncomouse 
 
 Oncomouse was originally produced to further cancer research by inserting an Oncogene 
that promoted tumor growth in the mouse.  With a tumor present, scientists could start to study, 
learn, and develop new ways to treat them.  The invention of the Oncomouse raised two issues; 
one being that this new patent dealt with a high-order animal, should patents be granted to 
mammals, and the second was the moral implications of the suffering caused to the animal 
versus the medical benefits. 
 
 April 12th, 1988 Patent NO. 4,736,866 was awarded to Harvard University geneticist 
Philip Leder and University of California’s Timothy Stewart.  For the first time in United States 
history an Institution gained rights to a living animal. Their claim included: A transgenic non-
human mammal all of whose germ cells and somatic cells contain recombinant activated 
oncogene sequence introduced into said mammal, or an ancestor of said mammal, at an 
embryonic stage (Woessner, 1999).  Although the claim explicitly excludes human patenting, it 
still caused much controversy. Many believed that this was too broad of a claim; it encompassed 
not only the rights of the animal and its Oncogene, but also its ancestry as well. 
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 The Oncomouse’s claim met all three of the Patent and Trade Offices Requirements.  
Since animals and genetic sequences are created naturally, some said it wasn’t possible for living 
matter to be novel, others argued that transgenic biotechnology drastically changed the organism.  
So much so, that it differs greatly from its original form, making it a novelty, like Oncomouse. 
The utility of that patent was found in its medical benefits.  It had great potential in assisting the 
field of medicine, pharmaceuticals, and disease models.  However, the realistic aspect of the 
product can be misperceived.  The amount of animal suffering compared to the actual medical 
benefit from it needs to be accounted for when reviewing a patent.   
The Patent and Trade Office is now required to examine the reasons behind a rejection of 
an invention.  The non-obviousness requirement in Biotechnology can be at times misleading, 
therefore in 1995, amendment 35 U.S.C. 103 was reviewed and changed to  include that “ in 
order to ascertain the obviousness of an invention, the invention must viewed in light of other 
inventions in the prior art,” (Walter, 1997).  Controversy arose where others believed that even 
though the patent met all three requirements, it was a little too much of a stretch, which fueled 
the opinion of them having such a wide claim on the organism.  
 On January 19th, 2000, DuPont reached an agreement with Harvard University & the 
National Institute of Health for an exclusive license of Oncomouse in exchange for further 
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funding Harvard.  DuPont increased business by distributing the Oncomouse through a license 
agreement to Taconic.   
 
 
 
 
Founded in 1952, Taconic has evolved into a major international supplier of pathogen-
free lab animals.  Although this opened up the mouse to be used by a broader spectrum of 
scientists for various studies, there were still guidelines associated with patent.  Taconic requires 
companies and scientists to comply with a contract which includes submission of annual reports 
of their studies, which many find a hassle and unnecessary.  Also, by having to pay for a 
commercial licensing fee, many believed that research would be restricted. 
 
 
 
 Due to the broad claims on the U.S. Oncomouse patent, the Patent and Trade Office made 
adjustments to narrow down terms of agreements on Transgenic Patents.  This way no single 
company can control a patent, which allows them to set competition for other companies.  To 
deny technology’s advancement would go against the definition of a patent itself.  Needless to 
say, the Oncomouse caused quite a stir in the world, and is now the precident for attempts at 
animal and living organism patents today.  
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Oncomouse Abroad 
 
Much of the same debate and controversy that surrounded the Oncomouse decision in the 
United States was seen abroad, in Europe, where their final ruling on the issue wasn’t concluded 
until 2004.  The European Patent Office decided this very complex case by applying the 
European Patent Convention standards to the Oncomouse Patent.  They used two important 
provisions to conclude their findings.  One being Article 53(A) which states and excludes 
inventions that “the publication or exploitation of which would be contrary to ordre public or 
morality”.   
 
 
 
 
The second key article was Article 53 (b) which excludes patents on “animal varieties or 
essentially biological processes for the production of …animals”(Bioethics and patent law.com).  
They also applied the utilitarian balancing test to address the case.  The test looked at the 
suffering of the mouse versus the potential medical benefits.  The European Patent Office 
concluded that the benefits in cancer research to be seen from allowing this patent outweighed 
the moral implication of testing on animals.  They did revise their original application to apply 
specifically to mice, and not animals in general.  In a similar case of the Upjohn Mouse, the 
utilitarian approach was used once again.  The Upjohn patent was for a mouse that was 
introduced with a hair loss gene, and would be used for the treatment of balding and wool 
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production.  The European Patent Office ruled against the patent, stating that the medical benefit 
didn’t outweigh the animal suffering that would be caused.   
In 2002, The Supreme Court of 
Canada made a final ruling over the 
Oncomouse which had initially been rejected 
under its first examination.  The initial 
rejection was based on the fact that 
transgenic animals didn’t fall under the 
definition of an invention.  The final ruling 
concluded that because Oncomouse was a 
high-order animal, it could not be patentable.  
They based their findings off the 
interpretation of “manufacture or composition of matter”, which has constantly been debated.  
They said that “Composition of Matter” was interpreted as “ingredients or substances that had 
been combined or mixed together by a person, and that the word “Manufacture” was understood 
as a “non living mechanistic product or process”(Bioethics and Patent Law).  Basically, 
multicellular microorganisms in the initial stage (as a human created mixture used to make the 
mouse) was patentable, but the actual creation and body of the mouse was not patentable. 
 
Positives of Animal Patents 
 
The ability to create patents and give entitlement rights allows for continuing 
advancements science and technology in general, but allowing Intellectual Property Rights to 
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apply to life forms specifically enhances the quality of Transgenic research and Biotechnology.  
The United States has been a leading country in bioethics and transgenic research, and has 
discussed not just animal patenting, but the issue of human gene patenting as well. 
 
 
 
 The issue of Animal Patents allowed for the next step in biotechnological research of the 
human genome.  Although a sure conclusion on the topic of human gene patents is still up in the 
air to this day, it is clear to see the potential benefits.  Disease research, food production, and the 
medicines that can address the worlds health issues all fall under the umbrella of transgenic 
research today.  Morality and ethics will always linger in the discussion of the issue, which is 
often complex.  Methods such as the Utilitarian Test used by the European Patent Office will 
assist in the decision making process of this controversial topic. 
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Negatives of Animal Patents 
Probably the most obvious drawback to Animal Patents is the suffering caused to the 
animal during the research.  PETA, CELA, and BUAV are some of the animal activist groups 
that are challenging the Trangenic Research used today.  A constant source of support for the 
groups is found in the Animal Welfare Act.  This piece of legislation provides protection of 
“…any live or dead dog, cat nonhuman primate, guinea pig, hamster, rabbit or other warm-
blooded animal, which is being used , or is intended for use, in research, teaching, testing, 
experimentation, or exhibition purposes, or as a pet”(Perzigian, 2003). Notice that this Act 
specifically excludes “birds, rat…mice..bred for use in research, and horses not used for research 
purposes, and other farm animals such as, but not limited to livestock or poultry.”  Where there’s 
a push, there will always be a resistance and 
compromise is the only way to continue looking 
after the well being of animals while still 
advancing in the care of humans.  Although one 
could say, as stated above, that animal patenting 
cracked the door open to the consideration of 
human gene patenting, and this could be a great 
benefit to society and technology, others disagree.  Experimenting with human genes leads to 
studies and applications of the technologies on humans themselves, which is the last phase of 
testing on any pharmaceutical today.  Much of the world is not ready to fully open that door to 
human gene patenting and testing. 
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Animal Patents Since Oncomouse 
 
 Currently there are around 670 animal patents in existence world wide, used for 
biotechnology and medical research.  Now there are several patented mice used for the research 
of the major health issues including HIV and 
Alzheimer’s.  Transgenic cows, pigs, and fish 
have all been patented including a wide variety of 
others.  There are a staggering number of court 
cases that continue to run through the legal system 
today and will continue as advancements continue 
to improve society.  How far will transgenic 
research go?  No one can truly say, but currently there’s much debate over animal-human 
chimeras, and who knows much farther research could truly go from there. 
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CONCLUSIONS 
 
This project investigated various aspects of transgenic animals such as what they are, 
how they are made, the five main catagories of transgenic animals created to date, and the legal 
and ethical battles that surround the topic.  With the large growth of the industry, transgenic 
research has gone from a hit or miss experiment to a highly efficient business, teaching us vast 
amounts of information regarding human disease, pharmaceutical production, organ 
transplantation, and the functions of biological molecules.  While the process of creating 
transgenic animals is nowhere near efficient, further research will not only allow greater benefits 
to be discovered, but it could also lead to a more humane way of treating those animals.  
Regarding legalities, we believe that legislation should be passed to ensure that transgenic 
animals are used responsibly (transgenic fish should not be released into the wild), ensure animal 
suffering is minized, and ensure their safety.  With intelligent guidelines in place, transgenic 
technology should be allowed to prosper, as the medical benefits are too great to ignore, 
continuing to improve their contributions to humanity. 
 
